Teva launches ADASUVE® in U.S.
3 March 2014 | By Teva
The first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults...
List view / Grid view
News
New Phase III data show tiotropium* Respimat® effective across asthma severities
3 March 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities...
US FDA approves Bydureon® Pen (exenatide extended-release for injectable suspension) for once-weekly treatment of adults with type 2 diabetes
3 March 2014 | By AstraZeneca
AstraZeneca announced that the US Food and Drug Administration has approved the BYDUREON® Pen 2 mg as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes...
Inside Raman UK Seminar 2014
3 March 2014 | By Renishaw
Renishaw’s Raman spectroscopy team will be hosting its next Inside Raman seminar on Tuesday 8th and Wednesday 9th April 2014...
Novartis marks Rare Disease Day with call for more research to understand and find treatments for rare diseases
28 February 2014 | By Novartis
Novartis joins the global rare disease community in recognition of Rare Disease Day by calling for a global exchange of ideas to deepen the understanding of rare diseases and help address a significant unmet medical need...
CHMP issues positive opinion for tablet formulation of Merck’s NOXAFIL® (posaconazole)
28 February 2014 | By Merck
Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of a new, investigational tablet formulation of NOXAFIL®...
GSK announces submission to U.S. regulatory authorities for Promacta™ (eltrombopag) for severe aplastic anaemia
28 February 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for Promacta™...
New release makes wide range of Cresset’s drug discovery software available through Pipeline Pilot interface
27 February 2014 | By kdm communications
Cresset is pleased to announce the release of our latest set of Pipeline Pilot components V2.0.0, including new tools for 3D visualization of field patterns, SAR data analysis and 3D-QSAR modeling...
Election of employee representatives to the Board of Directors of Novo Nordisk A/S
27 February 2014 | By Novo Nordisk
The employees of Novo Nordisk A/S have conducted the election of employee representatives to the Board of Directors of Novo Nordisk A/S...
Novartis extends leadership in clinical trial data transparency, reinforcing its support of clinical research and innovation
26 February 2014 | By Novartis
Novartis announced additional steps to extend its leadership in clinical trial data transparency...
US FDA approves orphan drug MYALEPT™ (metreleptin for injection)
26 February 2014 | By AstraZeneca
AstraZeneca announced the FDA approved orphan drug MYALEPT™ , which is indicated as an adjunct to diet as replacement therapy for the treatment of complications of leptin deficiency in patients with congenital or acquired generalised lipodystrophy...
New TouchTools™ PCR Wizard aids automated PCR set-up
26 February 2014 | By kdm communications
Tecan has launched the TouchTools™ PCR Wizard, an easy-to-use Freedom EVOware® add-on offering straightforward automation of PCR reaction set¬¬up on Freedom EVO® platforms...
Rare Disease Day 2014 – twelve new orphan medicines available to patients over the past year
25 February 2014 | By The European Medicines Agency
Over the past twelve months, a total of 12 medicines for the treatment of rare diseases were recommended for marketing authorisation by the European Medicines Agency’s Committee for Medicinal Products for Human Use...
Novartis shareholders approve all resolutions proposed by Novartis Board of Directors
25 February 2014 | By Novartis
A strong majority of Novartis shareholders today followed the Board of Directors' recommendations for all proposed resolutions at the Group's Annual General Meeting...
Ranbaxy suspends shipments of active pharmaceutical ingredients (APIs) produced at Indian plants
25 February 2014 | By Daiichi Sankyo Company
Daiichi Sankyo has announced that its consolidated subsidiary, Ranbaxy Laboratories, will temporarily suspended shipments of active pharmaceutical ingredients (APIs) produced at its Toansa and Dewas plants in India.
